We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Consensus and Guidelines · August 12, 2021

Chemotherapy and Targeted Therapy for Patients With Endocrine-Pretreated or HR− HER2− Metastatic Breast Cancer: ASCO Guideline Update

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update
J. Clin. Oncol 2021 Jul 29;[EPub Ahead of Print], B Moy, RB Rumble, SE Come, NE Davidson, A Di Leo, JR Gralow, GN Hortobagyi, D Yee, IE Smith, M Chavez-MacGregor, R Nanda, HL McArthur, L Spring, KE Reeder-Hayes, KJ Ruddy, PS Unger, S Vinayak, WJ Irvin, A Armaghani, MA Danso, N Dickson, SS Turner, CL Perkins, LA Carey

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading